Page 198 - 2019_02-Haematologica-web

M. Gaignage et al. References
1. Appelbaum FR. Hematopoietic cell trans- plantation from unrelated donors for treat- ment of patients with acute myeloid leukemia in first complete remission. Best Pract Res Clin Haematol. 2007;20(1):67-75.
2. Mahmoud HK, Elhaddad AM, Fahmy OA, et al. Allogeneic hematopoietic stem cell transplantation for non-malignant hemato- logical disorders. J Adv Res. 2015;6(3):449- 458.
3. Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant. 2008;41(2):119-126.
4. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561.
5. Choi SW, Reddy P. Current and emerging strategies for the prevention of graft-versus- host disease. Nat Rev Clin Oncol. 2014;11(9):536-547.
6. Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experi- mental systems instructing clinical practice. Blood. 2014;124(3):354-362.
7. Couriel DR, Saliba R, de Lima M, et al. A phase III study of infliximab and corticos- teroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009;15(12):1555-1562.
8. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling aug- ments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood. 2009;114(4):891-900.
9. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus- host disease. Blood. 2009;113(10):2352- 2362.
10. Marillier RG, Uyttenhove C, Goriely S, Marbaix E, Van Snick J. IL-27p28 is essential for parent-to-F1 acute graft-versus-host dis- ease. Eur J Immunol. 2014;44(7):2064-2073.
11. Belle L, Agle K, Zhou V, et al. Blockade of interleukin 27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing FOXP3 expression. Blood. 2016;128(16):2068-2082.
12. Yoshida H, Hunter CA. The immunobiolo- gy of interleukin-27. Annu Rev Immunol. 2015;33:417-443.
13. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity. 2002;16(6):779-790.
14. Yoshida H, Nakaya M, Miyazaki Y. Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol. 2009;86 (6):1295-1303.
15. Dibra D, Cutrera JJ, Li S. Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30. J Immunol. 2012;188 (8):3709-3715.
16. Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal- transducing receptor for IL-27. J Immunol. 2004;172(4):2225-2231.
17. Villarino AV, Larkin J, 3rd, Saris CJ, et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol. 2005;174(12):7684-7691.
18. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol.
2007;25:221-242.
19. Cohen JL, Trenado A, Vasey D, Klatzmann
D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-406.
20. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft- versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
21. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
22. Gaignage M, Marillier RG, Uyttenhove C, et al. Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells. Immun Inflamm Dis. 2017;5(2):200-213.
23. Bloom ML, Wolk AG, Simon-Stoos KL, Bard JS, Chen J, Young NS. A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol. 2004;32(12):1163- 1172.
24. Robb RJ, Kreijveld E, Kuns RD, et al. Type I- IFNs control GVHD and GVL responses after transplantation. Blood. 2011;118(12): 3399-3409.
25. Ammann CG, Messer RJ, Peterson KE, Hasenkrug KJ. Lactate dehydrogenase-ele- vating virus induces systemic lymphocyte activation via TLR7-dependent IFNalpha responses by plasmacytoid dendritic cells. PLoS One. 2009;4(7):e6105.
26. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-depen- dent signaling pathway. Nat Immunol. 2002;3(2):196-200.
27. Miller RL, Meng TC, Tomai MA. The antivi- ral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 2008;21(2): 69-87.
28. Holbrook BC, Kim JR, Blevins LK, et al. A Novel R848-conjugated inactivated influen- za virus vaccine is efficacious and safe in a neonate nonhuman primate model. J Immunol. 2016;15(2):555-564.
29. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine pro- duction with the immune response modi- fiers, R-848 and imiquimod. Cell Immunol. 1999;191(1):10-19.
30. Baenziger S, Heikenwalder M, Johansen P, et al. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood. 2009;113(2):377-388.
31. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interfer- ons in antiviral defense. Science. 1994;264(5167):1918-1921.
32. Uyttenhove C, Marillier RG, Tacchini- Cottier F, et al. Amine-reactive OVA multi- mers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in L. major infection. J Leukoc Biol. 2011;89(6):1001-1007.
on acute graft-versus-host disease patholo-
gies. Blood. 1998;91(11):4051-4055.
35. Giroux M, Delisle JS, Gauthier SD, et al. SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and gran- ulocyte-mediated tissue damage. Blood.
2011;117(5):1734-1744.
36. Hattori H, Matsuzaki A, Suminoe A, et al.
Polymorphisms of transforming growth fac- tor-beta1 and transforming growth factor- beta1 type II receptor genes are associated with acute graft-versus-host disease in chil- dren with HLA-matched sibling bone mar- row transplantation. Bone Marrow Transplant. 2002;30(10):665-671.
37. Penack O, Holler E, van den Brink MR. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood. 2010;115(10): 1865-1872.
38. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107(12): 1581-1589.
39. Calcaterra C, Sfondrini L, Rossini A, et al. Critical role of TLR9 in acute graft-versus- host disease. J Immunol. 2008;181(9):6132- 6139.
40. Taylor PA, Ehrhardt MJ, Lees CJ, et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008;112(8): 3508-3516.
41. Jasperson LK, Bucher C, Panoskaltsis- Mortari A, et al. Indoleamine 2,3-dioxyge- nase is a critical regulator of acute graft-ver- sus-host disease lethality. Blood. 2008;111(6):3257-3265.
42. Assier E, Marin-Esteban V, Haziot A, Maggi E, Charron D, Mooney N. TLR7/8 agonists impair monocyte-derived dendritic cell dif- ferentiation and maturation. J Leukoc Biol. 2007;81(1):221-228.
43. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415.
44. Markey KA, Banovic T, Kuns RD, et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood. 2009;113(22):5644-5649.
45. Van LP, Bardel E, Gregoire S, et al. Treatment with the TLR7 agonist R848 induces regula- tory T-cell-mediated suppression of estab- lished asthma symptoms. Eur J Immunol. 2011;41(7):1992-1999.
46. Zogas N, Karponi G, Iordanidis F, et al. The ex vivo toll-like receptor 7 tolerance induc- tion in donor lymphocytes prevents murine acute graft-versus-host disease. Cytotherapy. 2018;20(1):149-164.
47. Baron C, Somogyi R, Greller LD, et al. Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med. 2007;4(1):e23.
48. Ranges GE, Figari IS, Espevik T, Palladino MA Jr. Inhibition of cytotoxic T cell develop- ment by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166(4):991-
33. Lowenthal JW, Corthesy P, Tougne C, Lees
R, MacDonald HR, Nabholz M. High and 998.
low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with mono- clonal anti-receptor antibody PC61. J Immunol. 1985;135(6):3988-3994.
34. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies
49. Rahman AH, Taylor DK, Turka LA. The contribution of direct TLR signaling to T cell responses. Immunol Res. 2009;45(1):25-36.
50. Dominguez-Villar M, Gautron AS, de Marcken M, Keller MJ, Hafler DA. TLR7 induces anergy in human CD4(+) T cells. Nat Immunol. 2015;16(1):118-128.
402
haematologica | 2019; 104(2)